Cytokinetics (NASDAQ:CYTK) Price Target Raised to $88.00

25 Dec 2025, 01:18 by Jessica Moore · The Cerbat Gem

Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective upped by Citizens Jmp from $78.00 to $88.00 in a report issued on Monday morning,Benzinga reports. Citizens Jmp currently has a market outperform rating on the biopharmaceutical company’s stock.

Several other analysts have also recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Cytokinetics in a research report on Wednesday, October 8th. The Goldman Sachs Group set a $95.00 price target on Cytokinetics and gave the company a “buy” rating in a report on Thursday, December 18th. Barclays increased their target price on shares of Cytokinetics from $82.00 to $87.00 and gave the company an “overweight” rating in a research report on Monday. HC Wainwright raised their target price on shares of Cytokinetics from $120.00 to $136.00 and gave the company a “buy” rating in a research note on Monday. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Cytokinetics in a research note on Monday. Fifteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $83.61.

Check Out Our Latest Research Report on CYTK

Cytokinetics Stock Up 0.9%

NASDAQ:CYTK opened at $63.86 on Monday. The business’s 50 day moving average is $62.89 and its two-hundred day moving average is $49.20. Cytokinetics has a 52 week low of $29.31 and a 52 week high of $70.98. The company has a market cap of $7.81 billion, a PE ratio of -10.15 and a beta of 0.58.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.59) by $0.05. The company had revenue of $1.94 million during the quarter, compared to the consensus estimate of $6.05 million. The company’s revenue for the quarter was up 318.1% on a year-over-year basis. During the same period last year, the business posted ($1.36) EPS. As a group, sell-side analysts expect that Cytokinetics will post -5.24 EPS for the current fiscal year.

Insider Buying and Selling at Cytokinetics

In related news, Director Wendell Wierenga sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $66.14, for a total value of $1,322,800.00. Following the completion of the sale, the director owned 32,444 shares in the company, valued at approximately $2,145,846.16. This represents a 38.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Andrew Callos sold 1,042 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $65.96, for a total transaction of $68,730.32. Following the completion of the transaction, the executive vice president directly owned 50,660 shares of the company’s stock, valued at $3,341,533.60. This represents a 2.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 168,494 shares of company stock valued at $10,811,018 over the last three months. 2.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Cytokinetics

A number of institutional investors have recently bought and sold shares of CYTK. Hudson Bay Capital Management LP grew its stake in Cytokinetics by 15.4% during the 3rd quarter. Hudson Bay Capital Management LP now owns 182,131 shares of the biopharmaceutical company’s stock valued at $10,010,000 after acquiring an additional 24,345 shares in the last quarter. Swiss Life Asset Management Ltd purchased a new position in Cytokinetics during the third quarter valued at approximately $283,000. CIBC Private Wealth Group LLC increased its stake in Cytokinetics by 8.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 3,484 shares of the biopharmaceutical company’s stock valued at $191,000 after buying an additional 261 shares during the period. CIBC Bancorp USA Inc. acquired a new position in Cytokinetics in the 3rd quarter valued at approximately $684,000. Finally, Coldstream Capital Management Inc. purchased a new stake in Cytokinetics in the 3rd quarter worth approximately $261,000.

Key Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

Positive Sentiment: Major commercial catalyst — the company’s cardiology drug Myqorzo (aficamten) received FDA approval, moving Cytokinetics into a commercial‑stage biotech with an immediate revenue runway; this is the primary bullish driver. Article Title
Positive Sentiment: Analyst support and price‑target lifts — several brokers have raised price targets and reiterated Buy/Outperform stances (Citizens/JMP raised to $88; Needham, Morgan Stanley and others maintaining favorable ratings), reinforcing upside expectations from the commercial launch. Article Title Article Title
Positive Sentiment: Options flow: unusually heavy call buying (large block activity) suggests traders are positioning for further upside around the news and near‑term catalysts. Article Title
Neutral Sentiment: HC Wainwright trimmed Q4 and FY2025 EPS estimates slightly (small downward revisions) but kept a Buy rating and a $136 price target — a modest near‑term negative to estimates but not a change in conviction. (Research note summarized by MarketBeat)
Neutral Sentiment: Short‑interest report shows effectively zero reported short interest for December (likely a data anomaly); does not meaningfully change the supply/demand picture today.
Negative Sentiment: Insider selling — director Wendell Wierenga sold 20,000 shares at ~$66.14 on Dec. 22 (SEC Form 4 filed). Insider sales can be read as a cautionary signal by some investors even if they’re for diversification/liquidity reasons. SEC Filing Article Title

About Cytokinetics

(Get Free Report)

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.